Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (171-180 of 337) with videos related to

Pageof 34
Sort By:
Vaccine|March 25, 2020
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatusGustavo H Dayan, Edith Langevin, Peter B Gilbert, et al.
The Journal of Infectious Diseases|August 19, 2005
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccinePeter B Gilbert, Marta L Ackers, Phillip W Berman, et al.
The Journal of Infectious Diseases|December 2, 2017
Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin AmericaZoe Moodie, Michal Juraska, Ying Huang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 15, 2022
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials dataDani Cohen, Shai Ashkenazi, Rachel Schneerson, et al.
Plos One|December 14, 2018
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic diseaseChloé Pasin, M Elizabeth Halloran, Peter B Gilbert, et al.
Open Forum Infectious Diseases|January 19, 2023
Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy TrialYouyi Fong, Ying Huang, Bhavesh Borate, et al.
Biorxiv : the Preprint Server for Biology|June 23, 2021
Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning StrategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
Viruses|January 22, 2022
Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning StrategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
Vaccine|July 2, 2022
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021Peter B Gilbert, Richard Isbrucker, Nick Andrews, et al.
Plos One|February 11, 2016
Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy TrialsAndrew Fiore-Gartland, Bryce A Manso, David P Friedrich, et al.
Pageof 34

Showing results (171-180 of 337) with videos related to

Sort By:
Pageof 34
Vaccine|March 25, 2020
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatusGustavo H Dayan, Edith Langevin, Peter B Gilbert, et al.
The Journal of Infectious Diseases|August 19, 2005
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccinePeter B Gilbert, Marta L Ackers, Phillip W Berman, et al.
The Journal of Infectious Diseases|December 2, 2017
Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin AmericaZoe Moodie, Michal Juraska, Ying Huang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 15, 2022
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials dataDani Cohen, Shai Ashkenazi, Rachel Schneerson, et al.
Plos One|December 14, 2018
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic diseaseChloé Pasin, M Elizabeth Halloran, Peter B Gilbert, et al.
Open Forum Infectious Diseases|January 19, 2023
Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy TrialYouyi Fong, Ying Huang, Bhavesh Borate, et al.
Biorxiv : the Preprint Server for Biology|June 23, 2021
Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning StrategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
Viruses|January 22, 2022
Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning StrategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
Vaccine|July 2, 2022
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021Peter B Gilbert, Richard Isbrucker, Nick Andrews, et al.
Plos One|February 11, 2016
Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy TrialsAndrew Fiore-Gartland, Bryce A Manso, David P Friedrich, et al.
Pageof 34